Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
Published online before print January 9, 2008, doi:10.1212/01.wnl.0000286942.14552.51)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
01.wnl.0000286942.14552.51v1
70/16_Part_2/1418    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wahner, A. D.
Right arrow Articles by Ritz, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wahner, A. D.
Right arrow Articles by Ritz, B.
Related Collections
Right arrow Parkinson's disease/Parkinsonism
Right arrow Case control studies
Right arrow Risk factors in epidemiology
NEUROLOGY 2008;70:1418-1422
© 2008 American Academy of Neurology

Statin use and the risk of Parkinson disease

Angelika D. Wahner, PhD, Jeff M. Bronstein, MD, PhD, Yvette M. Bordelon, MD, PhD and Beate Ritz, MD, PhD

From the Department of Epidemiology (A.D.W., B.R.), UCLA School of Public Health; and the Department of Neurology (J.M.B., Y.M.B.), David Geffen School of Medicine at UCLA and the Greater Los Angeles Veterans Administration Medical Center, Los Angeles, CA.

Address correspondence and reprint requests to Dr. Angelika D. Wahner, UCLA School of Public Health, Box 951772, 650 Charles E. Young Drive, Los Angeles, CA 90095-1772

Objective: To investigate associations between statin (3-hxydroxy-3-methylglutaryl-coenzyme A reductase inhibitor) use and Parkinson disease (PD).

Methods: We used a population-based design to recruit 312 incident idiopathic PD cases and 342 controls from three rural California counties.

Results: We observed a higher frequency of statin use among controls vs cases (OR 0.45; 95% CI 0.29 to 0.71) and a strong dose-response relation. The strongest protective association between statin use and PD was observed in long-term (≥5 years) users (OR 0.37; 95% CI 0.18 to 0.78). There was no difference by gender or age. We noted 60 to 70% risk reductions for each individual statin except pravastatin.

Conclusion: Ascribing causality to these associations is premature and further studies are needed to confirm a potential neuroprotective role for statins in PD.

GLOSSARY: B-D test = Breslow-Day test; NO = nitric oxide; PD = Parkinson disease; PEG = Parkinson's Environment and Genes.

awahner{at}ucla.edu

e-Pub ahead of print on January 9, 2008, at www.neurology.org.

Supported by NIH—National Institute of Environmental Health Sciences Grants ES10544, U54ES12078, and pilot funding received from the SCEHSC # 5P30 ES07048, the American Parkinson Disease Association, and the SW PADRECC Veterans Administration.

Disclosure: The authors report no conflicts of interest.

Received May 7, 2007. Accepted in final form August 14, 2007.




This article has been cited by other articles:


Home page
 J. Neurosci.Home page
A. Ghosh, A. Roy, J. Matras, S. Brahmachari, H. E. Gendelman, and K. Pahan
Simvastatin Inhibits the Activation of p21ras and Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson's Disease
J. Neurosci., October 28, 2009; 29(43): 13543 - 13556.
[Abstract] [Full Text] [PDF]